NCT05848440 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 2, 2023

Primary Completion Date

November 13, 2023

Study Completion Date

November 13, 2023

Conditions

Non-alcoholic Steatohepatitis

Interventions

DRUG

AZD9550

Participants will be administered AZD9550 subcutaneously.

DRUG

AZD9550

Participants will be administered AZD9550 intravenously.

DRUG

Placebo

Participants will be administered matching volumes of placebo subcutaneously or intravenously.

Trial Locations (1)

Research Site, Harrow